Grand Junction, CONCT07007559Now EnrollingIRB Ready

Breast Cancer, Metastatic Clinical Trial in Grand Junction, CO

Access cutting-edge breast cancer, metastatic treatment through this clinical trial at a research site in Grand Junction. Study-provided care at no cost to qualified participants.

Sponsored by ALX Oncology Inc.

Quick Self-Assessment

See if you qualify for this Grand Junction location

Preparing your pre-screening questions…

Expert Care in Grand Junction

Access breast cancer, metastatic specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related breast cancer, metastatic treatment provided free

Apply for This Grand Junction Location

Check if you qualify for this breast cancer, metastatic clinical trial in Grand Junction, CO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Grand Junction

    Convenient for CO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Grand Junction site if eligible
  4. 4Begin participation

About This Breast Cancer, Metastatic Study in Grand Junction

The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic breast cancer who have previously received trastuzumab-deruxtecan. This substudy is actively recruiting. ASPEN-09-03 is a substudy under Master Protocol ASPEN-09, and additional substudies are as follows: * Metastatic colorectal cancer (CRC) - dose escalation phase to evaluate evorpacept in combination with other drugs. This substudy is not open. * Recurrent/metastatic head and neck cancer (HNSCC) - dose escalation phase to evaluate evorpacept in combination with other drugs. This substudy is not open.

Sponsor: ALX Oncology Inc.

Who Can Participate

Inclusion Criteria

Histologically confirmed invasive HER2+ breast cancer.
Received at least one prior line of therapy including T-DXd (ENHERTU) for locally advanced/metastatic HER2+ breast cancer. Prior neoadjuvant therapy which resulted in relapse within 6 months of completion of T-DXd will be considered a line of treatment for metastatic disease. Participants who discontinue T-DXd due to intolerance are considered eligible.
Progressed on or following the most recent line of therapy.
Eligible to receive one of the following chemotherapy options (capecitabine, eribulin, gemcitabine, paclitaxel or vinorelbine).
Measurable disease as defined by RECIST v1.1.
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) must be 0 to 1.
Life expectancy of at least 3 months.
Adequate renal function (estimated creatinine clearance ≥30 mL/min as calculated using the Cockcroft-Gault equation or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
Adequate liver function:
Total bilirubin ≤1.5 x upper limit of normal (ULN) (≤3.0 x ULN if the participant has documented Gilbert syndrome);
Aspartate and alanine transaminase (AST and ALT) ≤3 x ULN (≤5.0 x ULN if liver involved by metastatic disease).
Participants must have recovered from all AEs due to previous therapies, procedures, and surgeries to baseline severity or ≤Grade 1 per NCI CTCAE v5.0 except for AEs not deemed reversible and which do not constitute a safety risk by Investigator judgment.

Exclusion Criteria

Participants with known CNS metastases unless treated and stable prior to enrollment.
Prior exposure to any anti-CD47 or anti-SIRPα agent.
Any condition that would be contraindicated to receiving trastuzumab
Has a diagnosis of complete dihydropyrimidine dehydrogenase (DPD) deficiency or significant toxicity with prior flurouracil (5FU) based regimen
Following anti-cancer therapy with insufficient washout before start of treatment:
chemotherapy, hormonal therapy, radiation therapy or small molecule anti-cancer therapy within 14 days or 5 half-lives (whichever is shorter) of start of treatment.
Immune therapy or other biologic therapy (e.g., monoclonal antibodies, antibody-drug conjugates) for the treatment of cancer for: 28 days or 5 half-lives (whichever is shorter) of start of treatment).
History of autoimmune hemolytic anemia, autoimmune thrombocytopenia, or hemolytic transfusion reaction.
Had an allogeneic tissue/solid organ transplant.
Any active, unstable cardiovascular disease.
Intolerance to or who have had a severe allergic or anaphylactic reaction to antibodies or infused therapeutic proteins or participants who have had a severe allergic or anaphylactic reaction to any of the substances included in the study drug (including excipients).
Has an active autoimmune disease that has required systemic treatment in past 2 years.
Other primary malignancy within 2 years.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Grand Junction?

Yes, this clinical trial (NCT07007559) has an active research site in Grand Junction, CO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Breast Cancer, Metastatic Treatment Options in Grand Junction, CO

If you're searching for breast cancer, metastatic treatment options in Grand Junction, CO, this clinical trial (NCT07007559) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Grand Junction research site is actively enrolling participants for this clinical trial. You'll receive care from experienced breast cancer, metastatic specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all breast cancer, metastatic clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Grand Junction, CO

See all breast cancer clinical trials recruiting in Grand Junction — not just this study.

Browse Breast Cancer Trials in Grand Junction →

Browse More Trials by Condition

Breast Cancer TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Grand Junction?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Grand Junction, CO